# To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

> **NCT01738867** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 56 (actual)

## Conditions studied

- Alcoholism

## Interventions

- **DRUG:** GSK1521498
- **DRUG:** Naltrexone (NTX)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01738867
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-12
- **Primary completion:** 2014-05-27
- **Final completion:** 2014-05-27
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01738867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01738867, "To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01738867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*